---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-24-000103"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2024-11-18T23:59:59+00:00"
generated_at: "2026-05-29T22:57:25.502374+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Neurogene Q3 net loss $20.2M; positive NGN-401 data; $200M private placement

## Summary
- Q3 net loss $20.2M vs $14.6M YoY; cash & investments $139M as of Sep 30, 2024.
- First 4 NGN-401 participants at 1E15 vg showed consistent improvements; 28-52% RSBQ improvement.
- SAE at 3E15 vg dose; FDA allows continued enrollment at 1E15 vg; enrollment paused for protocol revision.
- NGN-101 CLN5 Batten program discontinued after RMAT application denied; options being evaluated.
- Closed ~$200M private placement extending cash runway into second half of 2027.

## SEC filing metadata
- accession: 0001404644-24-000103
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2024-11-18T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464424000103/0001404644-24-000103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464424000103/ngne-20241118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-24-000103
- JSON: https://secwatch.observer/filing/0001404644-24-000103.json
- Plain text: https://secwatch.observer/filing/0001404644-24-000103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.